clinical trial · NCT00127179
A Study of an Investigational Study Drug for Benign Prostatic Hyperplasia (0906-140)
Organon and Co·phase3·completed·n = 600
Benign Prostatic HyperplasiaMK0906, finasteride / Duration of Treatment: 48 weeksComparator: placebo / Duration of Treatment: 48 weeks
brief summary
The purpose of this trial is to determine the efficacy and safety of an investigational drug in patients with benign prostatic hyperplasia.
started
Jan 1, 2004
primary completion
Jul 1, 2005
completion
Jul 25, 2005
last updated
Aug 15, 2024
official title
MK0906 Phase III Double-Blind Comparative Study - Benign Prostate Hyperplasia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol